FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360607802> ?p ?o ?g. }

• W4360607802 abstract "You have accessJournal of UrologyCME1 Apr 2023MP13-07 AQUABLATION THERAPY® VS TRANSURETHRAL RESECTION OF THE PROSTATE: 5-YEAR OUTCOMES OF THE WATER RANDOMIZED CLINICAL TRIAL FOR MEDIUM-SIZED PROSTATES Kussil Oumedjbeur, Ahmed Ibrahim, Imad Matta, David-Dan Nguyen, Adel Arezki, Iman Sadri, David Bouhadana, Tawfik Elsherbini, Peter Gilling, Neil Barber, Mihir Desai, Alexis E. Te, Claus G. Roehrborn, and Kevin C. Zorn Kussil OumedjbeurKussil Oumedjbeur More articles by this author , Ahmed IbrahimAhmed Ibrahim More articles by this author , Imad MattaImad Matta More articles by this author , David-Dan NguyenDavid-Dan Nguyen More articles by this author , Adel ArezkiAdel Arezki More articles by this author , Iman SadriIman Sadri More articles by this author , David BouhadanaDavid Bouhadana More articles by this author , Tawfik ElsherbiniTawfik Elsherbini More articles by this author , Peter GillingPeter Gilling More articles by this author , Neil BarberNeil Barber More articles by this author , Mihir DesaiMihir Desai More articles by this author , Alexis E. TeAlexis E. Te More articles by this author , Claus G. RoehrbornClaus G. Roehrborn More articles by this author , and Kevin C. ZornKevin C. Zorn More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003233.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The WATER trial previously introduced Aquablation® as a safe and effective TURP alternative in the management of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH) for prostates <80 mL. To date, no long-term superiority endpoints have been reported for medium-sized prostates. In this subset analysis of the WATER cohort, we aim to compare the 5-year efficacy and safety of Aquablation® vs. TURP for the management of 50-80 mL prostates. METHODS: WATER is a double-blinded, multicenter and prospective randomized-controlled clinical trial for prostates 30-80 mL. 96 men with prostates 50-80 mL randomized to either Aquablation Therapy® or TURP from the initial cohort were retained for the subset analysis. Men received follow-up at 1, 3, 6 and 12 months, then annually up to 5 years. The primary efficacy endpoint was reduction of IPSS at 5-year follow-up. The primary safety endpoint was the occurrence of Clavien-Dindo postoperative complications grade 1 persistent (CD1P) and grade 2 (CD2) or higher at 6 months. Other measures included QoL, Qmax, PVR and MSHQ-EjD. RESULTS: Both study groups had comparable baseline voiding parameters and clinical demographics. Overall reduction in IPSS score was significantly higher in the Aquablation group across 5 years of follow-up (-14.1 vs. -10.8, p=0.02). Changes in QoL, Qmax and PVR were similar across groups (p>0.05). The Aquablation group displayed no changes in MSHQ-EjD score, while TURP yielded poorer questionnaire scores across all follow-ups (0.6 vs -2.1, p=0.01). The Aquablation group achieved a significantly lower rate of CD1P and CD2 or higher events at 6 months (RD=-23.1%; 95% CI [-29.9, -15.5], p=0.018). Among complications, post-operative ejaculatory dysfunction was notably lower in Aquablation® (RD=-21.9%; 95% CI [-32.5, -10.7], p=0.0005), while risk of bleeding was similar. The surgical and medical retreatment rate was also lower in Aquablation® (RD=-14.4%, 95% CI [-2.29, -30.4], p=0.015). CONCLUSIONS: Aquablation Therapy® yields better long-term efficacy and safety outcomes than TURP in the management of LUTS for prostate volumes of 50-80 mL within the WATER trial. This further supports adoption of Aquablation Therapy® over TURP for men with medium-sized prostates. Source of Funding: The trial is funded by PROCEPT BioRobotics. No funding was provided for the abstract creation © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e175 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kussil Oumedjbeur More articles by this author Ahmed Ibrahim More articles by this author Imad Matta More articles by this author David-Dan Nguyen More articles by this author Adel Arezki More articles by this author Iman Sadri More articles by this author David Bouhadana More articles by this author Tawfik Elsherbini More articles by this author Peter Gilling More articles by this author Neil Barber More articles by this author Mihir Desai More articles by this author Alexis E. Te More articles by this author Claus G. Roehrborn More articles by this author Kevin C. Zorn More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4360607802 created "2023-03-24" @default.
• W4360607802 creator A5008765130 @default.
• W4360607802 creator A5010193420 @default.
• W4360607802 creator A5017055388 @default.
• W4360607802 creator A5017714802 @default.
• W4360607802 creator A5017737725 @default.
• W4360607802 creator A5031034737 @default.
• W4360607802 creator A5036766039 @default.
• W4360607802 creator A5045045328 @default.
• W4360607802 creator A5047076289 @default.
• W4360607802 creator A5049019006 @default.
• W4360607802 creator A5050625725 @default.
• W4360607802 creator A5053728962 @default.
• W4360607802 creator A5063773495 @default.
• W4360607802 creator A5090804678 @default.
• W4360607802 date "2023-04-01" @default.
• W4360607802 modified "2023-10-16" @default.
• W4360607802 title "MP13-07 <i>AQUABLATION THERAPY</i> ® VS TRANSURETHRAL RESECTION OF THE PROSTATE: 5-YEAR OUTCOMES OF THE WATER RANDOMIZED CLINICAL TRIAL FOR MEDIUM-SIZED PROSTATES" @default.
• W4360607802 doi "https://doi.org/10.1097/ju.0000000000003233.07" @default.
• W4360607802 hasPublicationYear "2023" @default.
• W4360607802 type Work @default.
• W4360607802 citedByCount "0" @default.
• W4360607802 crossrefType "journal-article" @default.
• W4360607802 hasAuthorship W4360607802A5008765130 @default.
• W4360607802 hasAuthorship W4360607802A5010193420 @default.
• W4360607802 hasAuthorship W4360607802A5017055388 @default.
• W4360607802 hasAuthorship W4360607802A5017714802 @default.
• W4360607802 hasAuthorship W4360607802A5017737725 @default.
• W4360607802 hasAuthorship W4360607802A5031034737 @default.
• W4360607802 hasAuthorship W4360607802A5036766039 @default.
• W4360607802 hasAuthorship W4360607802A5045045328 @default.
• W4360607802 hasAuthorship W4360607802A5047076289 @default.
• W4360607802 hasAuthorship W4360607802A5049019006 @default.
• W4360607802 hasAuthorship W4360607802A5050625725 @default.
• W4360607802 hasAuthorship W4360607802A5053728962 @default.
• W4360607802 hasAuthorship W4360607802A5063773495 @default.
• W4360607802 hasAuthorship W4360607802A5090804678 @default.
• W4360607802 hasConcept C121608353 @default.
• W4360607802 hasConcept C126322002 @default.
• W4360607802 hasConcept C126894567 @default.
• W4360607802 hasConcept C141071460 @default.
• W4360607802 hasConcept C168563851 @default.
• W4360607802 hasConcept C2776235491 @default.
• W4360607802 hasConcept C2779478474 @default.
• W4360607802 hasConcept C2780768273 @default.
• W4360607802 hasConcept C535046627 @default.
• W4360607802 hasConcept C61434518 @default.
• W4360607802 hasConcept C71924100 @default.
• W4360607802 hasConceptScore W4360607802C121608353 @default.
• W4360607802 hasConceptScore W4360607802C126322002 @default.
• W4360607802 hasConceptScore W4360607802C126894567 @default.
• W4360607802 hasConceptScore W4360607802C141071460 @default.
• W4360607802 hasConceptScore W4360607802C168563851 @default.
• W4360607802 hasConceptScore W4360607802C2776235491 @default.
• W4360607802 hasConceptScore W4360607802C2779478474 @default.
• W4360607802 hasConceptScore W4360607802C2780768273 @default.
• W4360607802 hasConceptScore W4360607802C535046627 @default.
• W4360607802 hasConceptScore W4360607802C61434518 @default.
• W4360607802 hasConceptScore W4360607802C71924100 @default.
• W4360607802 hasIssue "Supplement 4" @default.
• W4360607802 hasLocation W43606078021 @default.
• W4360607802 hasOpenAccess W4360607802 @default.
• W4360607802 hasPrimaryLocation W43606078021 @default.
• W4360607802 hasRelatedWork W1559582992 @default.
• W4360607802 hasRelatedWork W1981573296 @default.
• W4360607802 hasRelatedWork W2061915797 @default.
• W4360607802 hasRelatedWork W2270907260 @default.
• W4360607802 hasRelatedWork W2744397717 @default.
• W4360607802 hasRelatedWork W2749567207 @default.
• W4360607802 hasRelatedWork W2784615683 @default.
• W4360607802 hasRelatedWork W3006945038 @default.
• W4360607802 hasRelatedWork W3031534085 @default.
• W4360607802 hasRelatedWork W3087731961 @default.
• W4360607802 hasVolume "209" @default.
• W4360607802 isParatext "false" @default.
• W4360607802 isRetracted "false" @default.
• W4360607802 workType "article" @default.